The Neuroinflammatory Etiopathology of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) by Julian A. G. Glassford
PERSPECTIVE
published: 17 February 2017
doi: 10.3389/fphys.2017.00088
Frontiers in Physiology | www.frontiersin.org 1 February 2017 | Volume 8 | Article 88
Edited by:
Elisabeth Lambert,
Baker IDI Heart and Diabetes Institute,
Australia
Reviewed by:
Alla B. Salmina,
Krasnoyarsk State Medical University
named after Prof.
V.F.Voino-Yasenetsky, Russia
Giorgos K. Sakkas,
University of St Mark and St John, UK
*Correspondence:
Julian A. G. Glassford
julianglassford@gmail.com
Specialty section:
This article was submitted to
Integrative Physiology,
a section of the journal
Frontiers in Physiology
Received: 27 September 2016
Accepted: 01 February 2017
Published: 17 February 2017
Citation:
Glassford JAG (2017) The
Neuroinflammatory Etiopathology of
Myalgic Encephalomyelitis/Chronic
Fatigue Syndrome (ME/CFS).
Front. Physiol. 8:88.
doi: 10.3389/fphys.2017.00088
The Neuroinflammatory
Etiopathology of Myalgic
Encephalomyelitis/Chronic Fatigue
Syndrome (ME/CFS)
Julian A. G. Glassford*
Independent Health Researcher and Consultant, Shrewsbury, UK
Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) is a debilitating
multi-systemic chronic illness of unknown etiology, classified as a neurological disorder
by the World Health Organization (WHO). The symptomatology of the condition appears
to emanate from a variety of sources of chronic neurological disturbance and associated
distortions, and chronicity, in noxious sensory signaling and neuroimmune activation.
This article incorporates a summary review and discussion of biomedical research
considered relevant to this essential conception perspective. It is intended to provide
stakeholders with a concise, integrated outline disease model in order to help demystify
this major public health problem. The primary etiopathological factors presented are:
(A) Postural/biomechanical pain signaling, affecting adverse neuroexcitation, in the
context of compression, constriction, strain, or damage of vertebral-regional bone and
neuromuscular tissues; (B) Immune mediated inflammatory sequelae, in the context of
prolonged immunotropic neurotrophic infection—with lymphotropic/gliotropic/glio-toxic
varieties implicated in particular; (C) A combination of factors A and B. Sustained glial
activation under such conditions is associated with oxidative and nitrosative stress,
neuroinflammation, and neural sensitivity. These processes collectively enhance the
potential for multi-systemic disarray involving endocrine pathway aberration, immune
and mitochondrial dysfunction, and neurodegeneration, and tend toward still more
intractable synergistic neuro-glial dysfunction (gliopathy), autoimmunity, and central
neuronal sensitization.
Keywords: chronic neurotrophic infection, glial hyper-activation, ME/CFS, neural sensitization, neuroimmune,
neuroinflammation, neurotoxic neuroexcitation, noxious nociception
INTRODUCTION
Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) is an idiopathic, heterogeneous
condition involving distortion of homeostasis across multiple organ systems. It is chiefly
characterized by myalgia, fatigue, neurocognitive dysfunction, and, critically, delayed muscle
recovery (Paul et al., 1999) and the intensification of symptoms following physical exertion:
“Post Exertional Malaise” (PEM), or “Post Exertional Neuroimmune Exhaustion” (PENE)
(VanNess et al., 2010).
This highly intrusive disease involves varying degrees of physical disability and cognitive deficits,
associated psychosocial difficulties, and significantly reduced quality of life (Winger et al., 2015)
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and life expectancy (Jason et al., 2006), across a patient
population numbering in the millions worldwide.
Complete/spontaneous recovery is extremely rare and
conventional treatment strategies rarely deliver even modest
direct, objective and, sustained symptomatic improvement.
Thus, ME/CFS constitutes a particularly enigmatic, debilitating,
and costly major public health issue, and the advancement of our
understanding of its essence, hence, a pressing area of biomedical
enquiry (Arroll, 2014).
The central focus of this work is the proposition that ME/CFS
constitutes the symptomatic manifestation of enhanced nervous
sensitivity attributable to a neuroinflammatory etiopathology
associated with abnormal nociceptive and neuroimmune activity.
The article reviews, highlights, and interconnects numerous
relevant disease features, processes, and concepts from the
biomedical literature, the ultimate aim of which is to provide
stakeholders with an instructive pathophysiological conceptual
framework.
DISCUSSION
Neuroanatomical Input
Postural and biomechanically induced neuroexcitatory
neuroinflammation has been posited as a partial explanation
for PEM/PENE (Rowe et al., 2013), and sustained muscle
activity and associated cortical excitability have been observed in
ME/CFS (Brouwer and Packer, 1994).
A number of clinical and physical therapy researchers
have, over the course of recent decades, variously formed
associations between ME/CFS, orthostatic intolerance, and
Ehlers-Danlos syndrome (Rowe et al., 1999), ME/CFS and joint
hypermobility (Barron et al., 2002), and ME/CFS and innate
(flat thoracic spine), osteochondritis, or trauma-linked vertebral
defects (Perrin, 2007). These issues, along with other connective
tissue disorders, fractures, and other factors that reduce range
of motion (ROM), a physical impediment common among
ME/CFS patients (Rowe et al., 2014), plus lengthy periods of
reduced movement of neuromuscular tissues, may be associated
with diminished neural motility and increased neuromuscular
tension/strain. Both during and 24 h following strain-inducing
experimental physical maneuvers, ME/CFS patients report
significantly greater symptom intensity elevation than do sham
exposed patient and healthy control cohorts (Rowe et al., 2016).
Along with neuropathies and peri-neural adhesions, these issues
represent potential ongoing sources of nociceptive input and
glial activation, resulting in enhanced peripheral and central
nervous sensitivity (Rowe et al., 2013). Peri-neural adhesions are
fibrous bonds proximal to nerve tissues, often formed during
post-operative/injury healing.
Any residual central sensitivity may, in turn, effect heightened
sensitivity of relevant portions of the peripheral nervous system
(PNS) to further input (Rowe et al., 2014). Furthermore, neurons
may continue to fire after the initiating stimulation has ceased
(Löscher and Ebert, 1996): a phenomenon observed in relation
to persistent, relatively low threshold stimulation, colloquially
referred to as “kindling” (Jason et al., 2011). Thus, the potential
exists for the emergence of an insidious peripheral-central
neurogenic sensitization loop, which would conceivably have the
power to modulate the impact of symptom worsening events in
ME/CFS. Hypothesized pathological products of these processes
include increased resting muscle tone, affected by enhanced
tension in/stimulation from proximal peri-neural fibers subject
to sensitization, and aggravation of vascular and autonomic tone
(Rowe et al., 2013).
Glial Activation
Nociceptive afferent input excites post-synaptic neurons and
may also be read by glia, triggering cellular responses e.g.,
via the stimulated neuronal release of chemical mediators that
bind to glial receptors (Ren and Dubner, 2008). Calcium ion
(Ca(2+)) influx into astrocytes following stimulation causes
central terminals of the nociceptor to release a host of neuroactive
signal molecules. These include the primary neuroexcitatory
neurotransmitter, glutamate, nitric oxide (NO), and pro-
inflammatory cytokines: Tumor necrosis factor alpha (TNF-α)
and interleukin-1 beta (IL-1β) (Ricci et al., 2009).
Activatedmicroglia behave similarly in responding to immune
challenge/inflammation (Renno et al., 1995), also inducing
superoxide production. Superoxide and NO are free radical
substrates of the potent, toxic oxidant peroxynitrite (ONOO–),
and hence sources of oxidative and nitrosative (O+NS) damage,
both individually and, particularly, when combined (Barger et al.,
2007). Along with the abovementioned stimuli, glia may also
be primed to respond more harshly by exposure to toxins
and electromagnetic fields (EMF), including non-ionizing, radio
frequency (RFR) electromagnetic radiation (EMR) (Hao et al.,
2010), autoimmune processes (Colton, 2009), and the effects of
aging (Norden and Godbout, 2012).
Glia propagate inflammatory signals and may cause chronic
pain e.g., involving allodynia and hyperalgesia (Yasui et al.,
2014), via the impact of bidirectional neuro-glial signaling;
glia may be activated by way of neuronal stimulation (as
described above) and the inflammatory cytokines that they
release may, in turn, couple to neuronal glutamate receptors,
thereby enhancing neuroexcitation (Ren and Dubner, 2008).
Synergistic interactions may result, prompting the dysregulation
of glial functions (gliopathy) and associated maladaptive hyper-
activation (microgliosis) (Ji et al., 2013). Magnetic resonance
imaging (MRI) reveals changes in the structure of the brain in
ME/CFS that may indeed be attributable to astrocyte dysfunction
(Barnden et al., 2011).
Gliopathy can come about following exposure to “glio-toxins”:
Immunosuppressive mycotoxins produced by certain species
of fungi, including house mold (Aikawa and Suzuki, 1985).
In one study, 93% of ME/CFS patients tested positive for
mycotoxins (Brewer et al., 2013), compared with 0% of controls
at similar detection thresholds (Hooper et al., 2009).∗ Gliopathies
are also believed to be initiated, more broadly, by concurrent
increases in extracellular glutamate and cytokine production
(Hulsebosch, 2008).
Enhanced glial activation results in neuroexcitation,
neuroinflammation and neurodegeneration, indicated by
significantly reduced white and gray matter in ME/CFS
(Puri et al., 2012), and hence (additional) glial multiplication
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subject to neuronal damage; at the symptomatic level it
is associated with cognitive deficits, common in ME/CFS
(Shanks et al., 2013), and depressive-like behavior
(Norden and Godbout, 2012), also fairly common in the
condition (Maes and Twisk, 2010). Widespread low-level
neuroinflammation has been detected in the brains of
ME/CFS patients, with neuropsychological symptom severity
associated with the level of neuroinflammation in one study
(Nakatomi et al., 2014), and with self-reported chronic pain
in another (Ickmans et al., 2015). Furthermore, animal
testing appears to indicate that microglial induction of IL-1β
may be a prerequisite for immunologically induced fatigue
(Ifuku et al., 2014),∗∗ and that gender-specific relationships
may exist concerning suppression of T cell contact-mediated
glial activation (Brahmachari and Pahan, 2010) and relative
prolongation of glial responses following neurotoxin exposure
(Ciesielska et al., 2009). These findings accord with numerous
human studies highlighting relatively high prevalence ofME/CFS
among females (Reyes et al., 2003).
∗ Elevated levels of pro-inflammatory cytokines paired with
O+NS stress are suspected as being behind mitochondrial
dysfunction in the disease (Morris and Maes, 2012).
Associated depletion of antioxidants may account for some
of the damage to fatty acids, proteins, and mitochondrial
DNA and membranes associated with ME/CFS, via the
activity of reactive oxygen and nitrogen species (ROS/RNS)
(Maes and Twisk, 2010). The anomalous presence of
mycotoxins may play a role here too (Brewer et al., 2013),
and EMR exposure represents a complicating factor
within this thematic e.g., given its capacity to influence
fungal activity/biotoxicity (Velizarov et al., 1999) and lipid
peroxidation (Mailankot et al., 2009).
∗∗ IL-1β mediates substances that may induce excitotoxicity
(Mohebiany and Schneider, 2013), and inflammatory cytokine
activity could play an important role in the aberration of
endocrine (Jason et al., 2011) and mitochondrial dysfunction
(Myhill et al., 2009).
Central Sensitivity
Peripheral pain can contribute to “central sensitization,” or
“wind-up”: The enhancement of nociceptive pathways in the
central nervous system (CNS), a process arguably manifest in
hyperalgesia in ME/CFS (Nijs et al., 2012) and sister condition
Fibromyalgia Syndrome (FMS) (Woolf, 2011), and one which
has been used to theoretically elucidate aspects of ME/CFS
symptomatology (Meeus and Nijs, 2007). Wind-up takes place
under long-term potentiation (LTP), in the context of temporal
summation effected by repetitive nociceptive stimulation (which
may be low/subclinical in intensity) (Woolf, 1991).
ME/CFS patients have demonstrably low nociceptive
thresholds of the muscle tissues (Vecchiet et al., 1996), and
many have significant cerebral (brain) hypoperfusion (Hamre,
1995), including in the parahippocampus (Gay et al., 2016)
and brain stem (Costa et al., 1995), which may contribute
to abnormal function of the locus ceruleus, involved in
the control of descending inhibitory nociceptive pathways
(Meeus and Nijs, 2007). Along with NO and pro-inflammatory
cytokine activity, excitotoxicity may play a role in migraine
pathogenesis (Longoni and Ferrarese, 2006). Migraines
have been detected in 82% of ME/CFS cases and factors
implicated in migraine pathology likely contribute to the type
of headaches and cognitive impairments seen in the disease.
Consistent with the above, the cortical spreading depression
(CSD) model of migraine describes dysfunction in brain
energetics, the brainstem, and thalamocortical tracts associated
with changes in cerebrovascular dynamics and ischemia
affecting loss of descending inhibitory nociceptive processes
(Rayhan et al., 2013).
Aberration of Endocrine Pathways
Pro-inflammatory cytokines can alter the metabolism of
serotonin (5-HT) and dopamine (Felger and Miller, 2012),∗
effecting dysregulation of associated neurotransmitters,
including glutamate, norepinephrine (NE, noradrenalin), and
corticosteroids. 5-HT and NE are the major neurotransmitters
involved in descending nociceptive modulation, and NE
increases blood flow/pressure by increasing vascular tone,
triggers glucose release, and can suppress neuroinflammation.
Glucocorticoid deficiencies∗∗ are associated with interrupted
nociceptive modulation, for example via the disruption
of neuroendocrine-mediated glial activation mechanisms
(Schwartzman, 2012).
∗ Serotonin status fluctuation (Badawy et al., 2005)
and dopaminergic modulation abnormalities
(Georgiades et al., 2003) have been observed in ME/CFS.
∗∗ Both increased resistance to glucocorticoid-immune
signaling (Kavelaars et al., 2000) and increased glucocorticoid
receptor sensitivity have been implicated in ME/CFS
(Visser et al., 2001).
Adenosine triphosphate (ATP) activity influences glutamate
and gamma-Aminobutyric acid (GABA) release, and hence the
glutamate:GABA ratio. GABA is the primary neuroinhibitory
neurotransmitter in the CNS. ATP depletion is observed in
ME/CFS (Morris and Maes, 2013), and is associated with N-
methyl-D-aspartate (NMDA) stimulation and hypersensitivity
(Pall, 2003). Furthermore, low neuronal energy production
markedly increases sensitivity to glutamate excitotoxicity
(Blaylock and Maroon, 2012). NMDA receptor activation
results in increased levels of ONOO– (Pall, 2003) and triggers
loss of mitochondrial membrane potential and apoptosis
(Hardingham et al., 2002).
Circulatory Abnormalities
ME/CFS patients tend to have low cardiac output and the vast
majority experience orthostatic intolerance (OI) (Miwa, 2015),
a manifestation of dysautonomia relating to inadequate
blood circulation and attributable to hypovolemia/blood
pooling in the extremities. Various regulatory
neurotransmitter/(neuro)endocrine abnormalities (Pall, 2007),
as well as (related) sympathetic nervous system (SNS) dominance
(Freeman and Komaroff, 1997), and diminished cardiac mass
(Hollingsworth et al., 2012), may account for such features.
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Additionally, cerebral vascular control appears closely related
to skeletal muscle pH, found to be elevated in ME/CFS at
rest (Jones et al., 2010), and it has been hypothesized that
compromised skeletal muscle cellular membrane function may
lead to a degree of acidity equalization between the skeletal
muscle intracellular environment (raised pH) and the blood
(lowered pH). Consistent with these relations, abnormally
prolonged cerebral vasoconstriction following orthostatic
challenge is routinely observed in ME/CFS (He et al., 2013);
this has ramifications for neural health, as per the links outlined
in the previous section, plus other deleterious effects including
cerebral hypoxia and neurocognitive deficits (Ocon, 2013).
Gene Activity
General statistical surveys are suggestive of a heritable aspect
to ME/CFS, with the relative risk of disease development
among first degree relatives almost 3 times the norm
(Albright et al., 2011). It is worth noting that inflammatory
reactivity is of course a function of genetic variation in cytokine
genotypes, which underpin the severity of “sickness behavior”
in ME/CFS (Vollmer-Conna et al., 2008) e.g., in the context of
chronic neurotropic infection (VanElzakker, 2013).
Polymorphism in the TNF-α promoter gene TNF-857 and
significant decrease of interferon-gamma (IFNγ) low producers
have been observed in ME/CFS (Carlo-Stella et al., 2006),
implying an inherent pro-inflammatory immunomodulatory
disposition. Patients have also been found to have
polymorphisms of transient receptor potential channels (TRPs):
TRPM1 and TRPM3 (Marshall-Gradisnik et al., 2015), affecting
mechanoreceptor nociceptive and mood-linked neurological
status, and appear to have peculiar genes and gene activity
relating more specifically to aspects of central nociception and
stress mediation (CDC, 2006). Abnormally high expression
of P2X purinoceptor 7 protein encoding P2RX7, a gene that
regulates nociception (and inflammatory pain in particular),
has been noted (Light et al., 2013) and there is also evidence
of an array of serotonergic genetic abnormalities; these include
differences in genes responsible for 5-HT production (Narita
et al., 2003) as well as distinct genotypic and allelic frequencies
of the 5-HT receptor 2A (5-HT2A) encoding HTR2A gene
(Bozzinia et al., 2012). 5-HT2A receptors are believed to mediate
neuronal excitation and anxiety, their expression appears to
be up-regulated post-infection (Couch et al., 2015), and their
antagonists have been shown to mitigate chronic pain (Bardin,
2011).
Evolution of Encumbrance Disorders
The term “encumbrance” is used in this article to denote the
constriction, strain, or damage of neuromuscular tissues, as well
as associated compression of proximal osseous tissues.
Core intensive/high neuro-dynamic intensity physical activity
increases the risk of encumbrance-linked health problems,
particularly during spinal development. Related risk factors
also include acute neuromuscular strains, neuropathies,∗ and
peri-neural adhesions, as well as relatively indirect processes
such as the evolution of connective tissue, hypermobility,
and inflammatory disorders. Such issues may be underpinned
by genetic vulnerability concerning/the epigenetic impact of
psychological trauma (Heim et al., 2009) and psychosocial stress
(Prins et al., 2008), together with a broader array of neurotoxic
(Giordano and Costa, 2012)/immunotoxic stressors (Dietert,
2014), on the development and functioning of (neuro)anatomic,
(neuro)endocrine, and (neuro)immune systems.
∗ Animal testing reveals that peripheral nerve injury
may alter blood-spinal cord barrier (BSCB) integrity
(Echeverry et al., 2011), and viruses, inflammatory cytokines,
RFR EMR, ONOO–, O+NS stress, and psychological stress
may similarly compromise the blood-brain barrier (BBB)
(Bested et al., 2001). This renders the central nervous system
(CNS) relatively vulnerable to the permeation of pollutants
from the blood.
Common postural risk factors associated with
constriction/biomechanical strain of neuromuscular tissues
subject to abnormal tension and related sensitivity may
include: (1) Flexion of the hip or ankle beyond 70 degrees;
(2) Flexion of the neck/arching of the back associated with
tucking of the chin and forward/stooped head positions;
(3) Lower back slumping/jamming/immobilization e.g., in
the absence of sufficient ischial support (Rowe et al., 2016).
Factor 3 is a potential source of decreased lumbar lordosis,
and constriction/compression of proximal dorsal root ganglia
(DRG) and osseous tissues, and hence of (enhanced) nociceptive
stimulation (Mörl and Bradl, 2013).
Relative inactivity may also have ramifications for
the health of neuromuscular tissues, for example via
heightened nociceptive/neuroinflammatory responses in
the context of enhanced neuromuscular tension/strain
resulting from diminished neurodynamic and neuromuscular
motility/flexibility (Rowe et al., 2013).
Chronic sleep deficiencies in ME/CFS influence insulin-
like growth factor 1 (IGF-1) synthesis, neural sensitivity
(Schuh-Hofer et al., 2013), and neurotoxin clearance
(Xie et al., 2013). IGF-1 is a hormone stimulated by growth
hormone, particularly during deeper “slow-wave” sleep; ME/CFS
patients typically experience little sleep at stages III and IV
(Fischler et al., 1997) and have lower serum levels of IGF-1
(Berwaerts et al., 1998), with quality of sleep correlated with
circulating levels of pro-inflammatory cytokines, and severity
and frequency of symptoms, in the disease (Milrad et al., 2017).
Additionally, pro-inflammatory cytokines appear to directly
dampen IGF-1 pathways (Puche and Castilla-Cortázar, 2012).
IGF-1 plays an important role in many biological processes,
notably including: Myelination (Liang et al., 2007) and
early recovery from demyelination (Mason et al., 2000),
and mitochondrial nutrient and inhibitory neurotransmitter
synthesis.
Neuroinflammatory Etiopathogenesis
The picture that emerges from the literature indicates
that disease pathogenesis is a function of the following
primary etiopathologies: (A) Chronic peripheral
nociception/neuroinflammation associated with encumbrance of
neuromuscular/osseous tissues (Figure 1); (B) Chronic immune
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activation associated with marked antigenic activity; (C) A
combination of factors A and B.
A) Under postural/biomechanical challenge, sensitive
neuromuscular tissues subject to encumbrance trigger
noxious nociceptive input and glial activity. Responding
glial cells propagate inflammatory signals, releasing pro-
inflammatory cytokines and effecting central nociceptor
terminal release of neuroactive molecules, including
glutamate and NO.
B) Persistent neuroimmune stimulation, above
systemic tolerance thresholds, associated with
inadequate immunological responses to neurotrophic
infection, often involving lymphotropic/gliotropic
microorganisms (Hickie et al., 2006), may lead to immune
FIGURE 1 | Encumbrance pathway “A.”
suppression/exhaustion. In the context of immunological
functional impairment tending toward autoimmunity
(Bradley et al., 2013), this may involve somewhat
circular processes of initial infection, inflammation,
paired with enhanced serotonin receptor expression
(Couch et al., 2015), and hence raised (inflammatory)
pain, immunodeficiency, and progression/reactivation of
opportunistic intercurrent (Smith and Thomas, 2015) and
latent infections (Broderick et al., 2010); well represented
among these pathogens (Nicolson et al., 2003) are those
known to target sites of autoimmune inflammation
(Posnett and Yarilin, 2005). Consistent with this picture,
recurrent viral infections and concordant chronic systemic
inflammation appear to be a hallmark of the disease (Raison
et al., 2009).
C) Neuromuscular tissue inflaming anatomical stimuli
modulate local immune responses. Equally, immune
stimulation affecting altered serotonergic receptor activity,
glial activation, and inflammation of neuromuscular tissues
proximal to infection sites also enhances sensitivity of
said tissues to postural/biomechanical stimulation. Neural
excitation threshold reduction affected by select pathogenic
strains may also play a role here (Oldstone, 1989).
Sufficiently acute/sustained exposure to glio-toxins (B, C) and/or
extracellular glutamate and pro-inflammatory cytokine elevation
stemming from other neuroinflammatory stimuli (A, B, C) is
associated with elevated, and potentially increasingly primed,
glial activity and sickness behavior, as well as neuroinflammtory
(excitotoxic) neurotoxicity and O+NS stress, and raised
peripheral nervous sensitivity. Signal molecules released in
FIGURE 2 | Effects of sustained glial activation.
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relation to these effects act as to lower the threshold and opening
characteristics of neuronal receptor channels, hence enhancing
central neuronal sensitivity. See Figure 2 for a basic model of
adverse products of glial activation and their downstream effects.
Sustained glial activation enhances the potential for
longer lasting, more intractable multi-systemic disarray,
including space for: Synergistic neuro-glial distortions (i.e.,
gliopathy/microgliosis), neuroendocrine pathway aberration,
mitochondrial dysfunction, and immunodeficiency; hence,
glial-simulative neurological activity may have the capacity to
fundamentally determine disease severity and prolongation.
Given that low-dose Naltrexone (LDN) inhibits glial activation,
the reported efficacy of this drug in ME/CFS and FMS would
appear consistent with this proposition (Younger et al., 2013).
Mitigation of Encumbrance Symptoms
Optimal management/treatment of the encumbrance-linked
abnormalities outlined in this article and the supporting
literature warrants further study (Rowe et al., 2014). At a
minimum, avoiding the noted “common postural risk factors”
(flexion/slumping) and intense/repetitive neuro-dynamic
movement of sensitive neuromuscular tissues is advisable. The
use of special furniture/accessories may aid relevant behavior
change e.g., rocking kneeling chairs/wobble cushions and
vertebral support belts/braces.
Manual physical therapy focused on mild functional exercises
and gentle stretching, intended to gradually increase ROM and
reduce neuromuscular tension, may prove beneficial. Physical
therapists should be aware, however, that the DRG may be
sensitive/inflamed and that manipulation of this region, as well
as direct nerve mobilization (particularly in the direction of
strain), has the capacity to exacerbate symptoms considerably
(Rowe et al., 2013).
Overcoming physical activity avoidance and facilitating
physical rehabilitation are considered important recovery goals
(Nijs et al., 2013). If progress here is to be optimally
sustained, then related endeavors will, thus, remain within
dynamic, individualized parameters, reflecting: Levels of strength
and stamina (Eyskens et al., 2015), peripheral sensitivity
(Staud et al., 2015), limited energy envelopes (Jason et al., 2009),
and delayed mitochondrial energy (Lengert and Drossel, 2015)
and muscular recovery (Paul et al., 1999).
Complementary dietary supplementation regimens might
include: Omega-3 PUFAs (Maes and Twisk, 2010), CoQ10
(Chang et al., 2012), Withania Somnifera (Ashwagandha, Indian
Ginseng) (Sankar et al., 2007), N-acetylcysteine (NAC) (Dean
et al., 2011),∗ vitamin B12 (Zoccolella et al., 2009), curcumin
(contained in turmeric) (Blaylock and Maroon, 2012), zinc
(Hambidge and Krebs, 2007), magnesium (Cox et al., 1991),
2-aminoethanesulfonic acid (L-Taurine) (Leon et al., 2009),
and carnitine (L-Carnitine) (Maes and Twisk, 2010).
These substances reportedly aid healthy modulation of
glutamatergic, neurotropic, and other relevant inflammatory
pathways, protection against/the reversal of excitotoxicity, the
rebalancing of glutamate:GABA, and mitochondrial and brain
function.
A precautionary approach may be considered sensible
with respect to additional factors that could conceivably
complicate pathophysiological processes outlined in this
article. These may include: Exposure to toxicants e.g.,
chemical pesticides (Dietert, 2014)/heavy metals (Giordano
and Costa, 2012), mold (Aikawa and Suzuki, 1985), and
both low frequency (ELF) (Rowland et al., 1998) and high
frequency RFR (Pall, 2016) EMFs/EMR, as well as psychological
stress (Prins et al., 2008), dehydration (Rowe et al., 1999), and
exhaustion (Blaylock and Maroon, 2012).
AUTHOR CONTRIBUTIONS
The author confirms being the sole contributor of this work and
approved it for publication.
ACKNOWLEDGMENTS
Special thanks to Megan Arroll, Mark Livingstone, Raymond
Perrin, and Peter Rowe for their feedback and encouragement.
REFERENCES
Aikawa, H., and Suzuki, K. (1985). Enteric gliopathy in niacin-
deficiency induced by CNS glio-toxin. Brain Res. 334, 354–356.
doi: 10.1016/0006-8993(85)90231-8
Albright, F., Light, K., Light, A., Bateman, L., and Cannon-Albright, L. (2011).
Evidence for a heritable predisposition to Chronic Fatigue Syndrome. BMC
Neurol. 11:62. doi: 10.1186/1471-2377-11-62
Arroll, A. (2014). Chronic Fatigue Syndrome What You Need to Know About
CFS/ME. London: Sheldon Press.
Badawy, A. A., Morgan, C. J., Llewelyn, M. B., Albuquerque, S. R., and Farmer,
A. (2005). Heterogeneity of serum tryptophan concentration and availability to
the brain in patients with the chronic fatigue syndrome. J. Psychopharmacol. 19,
385–391. doi: 10.1177/0269881105053293
Bardin, L. (2011). The complex role of serotonin and 5-HT receptors in chronic
pain. Behav. Pharmacol. 22, 390–404. doi: 10.1097/FBP.0b013e328349aae4
Barger, S. W., Goodwin, M. E., Porter, M. M., and Beggs, M. L.
(2007). Glutamate release from activated microglia requires the
oxidative burst and lipid peroxidation. J. Neurochem. 101, 1205–1213.
doi: 10.1111/j.1471-4159.2007.04487.x
Barnden, L., Crouch, B., Kwiatek, R., Burnet, R., Mernone, A., Chryssidis, S.,
et al. (2011). A brain MRI study of chronic fatigue syndrome: evidence of
brainstem dysfunction and altered homeostasis. NMR Biomed. 24, 302–1312.
doi: 10.1002/nbm.1692
Barron, D. F., Cohen, B. A., Geraghty, M. T., Violand, R., and Rowe, P.
C. (2002). Joint hypermobility is more common in children with chronic
fatigue syndrome than in healthy controls. J. Pediatr. 141, 421–425.
doi: 10.1067/mpd.2002.127496
Berwaerts, J., Moorkens, G., and Abs, R. (1998). Secretion of growth hormone in
patients with chronic fatigue syndrome. Growth Horm. IGF Res. 8(Suppl. 2),
127–129. doi: 10.1016/S1096-6374(98)80036-1
Bested, A. C., Saunders, P. R., and Logan, A. (2001). Chronic fatigue syndrome:
neurological findings may be related to blood–brain barrier permeability.Med.
Hypotheses 57, 231–237. doi: 10.1054/mehy.2001.1306
Blaylock, R. L., and Maroon, J. (2012). Natural plant products and extracts
that reduce immunoexcitotoxicity-associated neurodegeneration and
Frontiers in Physiology | www.frontiersin.org 6 February 2017 | Volume 8 | Article 88
Glassford The Neuroinflammatory Etiopathology of ME/CFS
promote repair within the central nervous system. Surg. Neurol. Int. 3:19.
doi: 10.4103/2152-7806.92935
Bozzinia, S., Boiocchib, C., Carlo-Stellaa, N., Ricevutic, G., and Cucciaa, M. (2012).
The possible underworld of Chronic Fatigue Syndrome from neurotransmitters
polymorphisms to disease. J. Neurol. Res. 2, 16–24. doi: 10.4021/jnr86w
Bradley, A. S., Ford, B., and Bansal, A. (2013). Altered functional B cell subset
populations in patients with chronic fatigue syndrome compared to healthy
controls. Clin. Exp. Immunol. 172, 73–80. doi: 10.1111/cei.12043
Brahmachari, S., and Pahan, K. (2010). Gender-specific expression of beta1
integrin of VLA-4 in myelin basic protein-primed T cells: implications
for gender bias in multiple sclerosis. J. Immunol. 184, 6103–6113.
doi: 10.4049/jimmunol.0804356
Brewer, J. H., Thrasher, J. D., Straus, D. C., Madison, R. A., and Hooper, D. (2013).
Detection of Mycotoxins in patients with chronic fatigue syndrome. Toxins 5,
605–617. doi: 10.3390/toxins5040605
Broderick, G., Fuite, J., Kreitz, A., Vernon, S., Klimas, N., and Fletcher, M. (2010).
A formal analysis of cytokine networks in Chronic Fatigue Syndrome. Brain
Behav. Immun. 24, 1209–1217. doi: 10.1016/j.bbi.2010.04.012
Brouwer, B., and Packer, T. (1994). Corticospinal excitability in patients
diagnosed with chronic fatigue syndrome. Muscle Nerve 17, 1210–1212.
doi: 10.1002/mus.880171012
Carlo-Stella, N., Badulli, C., De Silvestri, A., Bazzichi, L., Martinetti, M., Lorusso,
L., et al. (2006). A first study of cytokine genomic polymorphisms in CFS:
positive association of TNF-857 and IFNgamma 874 rare alleles. Clin. Exp.
Rheumatol. 24, 179–182.
CDC (2006). Press Briefing Transcripts: Chronic Fatigue Syndrome. Available online
at: http://www.cdc.gov/media/transcripts/t060420.htm (Accessed September
25, 2016).
Chang, Y., Huang, S., and Wang, S. (2012). Coenzyme Q10 inhibits the release
of glutamate in rat cerebrocortical nerve terminals by suppression of voltage-
dependent calcium influx and mitogen-activated protein kinase signaling
pathway. J. Agric. Food Chem. 60, 11909–11918. doi: 10.1021/jf302875k
Ciesielska, A., Joniec, I., Kurkowska-Jastrzebska, I., Cudna, A., Przybyłkowski, A.,
Członkowska, A., et al. (2009). The impact of age and gender on the striatal
astrocytes activation in murine model of Parkinson’s disease. Inflamm. Res. 58,
747–753. doi: 10.1007/s00011-009-0026-6
Colton, C. (2009). Heterogeneity of microglial activation in the innate
immune response in the brain. J. Neuroimmune Pharmacol. 4, 399–418.
doi: 10.1007/s11481-009-9164-4
Costa, D., Tannock, C., and Brostoff, J. (1995). Brainstem perfusion is impaired in
chronic fatigue syndrome. QJM 88, 767–773.
Couch, Y., Xie, Q., Lundberg, L., Sharp, T., and Anthony, D. (2015).
A model of Post-Infection Fatigue is associated with increased TNF
and 5-HT2A receptor expression in mice. PLoS ONE 10:e0130643.
doi: 10.1371/journal.pone.0130643. eCollection 2015
Cox, I. M., Campbell, M. J., and Dowson, D. (1991). Red blood cell
magnesium and chronic fatigue syndrome. Lancet 337, 757–760.
doi: 10.1016/0140-6736(91)91371-Z
Dean, O., Giorlando, F., and Berk, M. (2011). N-acetylcysteine in psychiatry:
current therapeutic evidence and potential mechanisms of action. J. Psychiatry
Neurosci. 36, 78–86. doi: 10.1503/jpn.100057
Dietert, R. R. (2014). Developmental immunotoxicity, perinatal programming, and
noncommunicable diseases: focus on human studies. Adv Med. 2014:867805.
doi: 10.1155/2014/867805
Echeverry, S., Shi, X., Rivest, S., and Zhang, J. (2011). Peripheral nerve
injury alters blood-spinal cord barrier functional and molecular integrity
through a selective inflammatory pathway. J. Neurosci. 31, 10819–10828.
doi: 10.1523/JNEUROSCI.1642-11.2011
Eyskens, J. B., Nijs, J., D’Août, K., Sand, A., Wouters, K., and Moorkens,
G. (2015). Timed loaded standing in female chronic fatigue syndrome
compared with other populations. J. Rehabil. Res. Dev. 52, 21–29.
doi: 10.1682/JRRD.2014.03.0086
Felger, J. C., and Miller, A. (2012). Cytokine effects on the basal ganglia and
dopamine function: the subcortical source of inflammatory malaise. Front.
Neuroendocrinol. 33, 315–327. doi: 10.1016/j.yfrne.2012.09.003
Fischler, B., Le Bon, O., Hoffmann, G., Cluydts, R., Kaufman, L., andDeMeirleir, K.
(1997). Sleep anomalies in the chronic fatigue syndrome. a comorbidity study.
Neuropsychobiology 35, 115–122. doi: 10.1159/000119331
Freeman, R., and Komaroff, A. (1997). Does the chronic fatigue syndrome
involve the autonomic nervous system? Am. J. Med. 102, 357–364.
doi: 10.1016/S0002-9343(97)00087-9
Gay, C., Robinson, M., Lai, S., O’Shea, A., Craggs, J., Price, D., et al. (2016).
Abnormal resting-state functional connectivity in patients with chronic fatigue
syndrome: results of seed and data-driven analyses. Brain Connect. 6, 48–56.
doi: 10.1089/brain.2015.0366
Georgiades, E., Behan, W., Kilduff, L., Hadjicharalambous, M., Mackie, E., Wilson,
J., et al. (2003). Chronic fatigue syndrome: new evidence for a central fatigue
disorder. Clin. Sci. 105, 213–218. doi: 10.1042/CS20020354
Giordano, G., and Costa, L. (2012). Developmental neurotoxicity: some old and
new issues. ISRN Toxicol. 2012:814795. doi: 10.5402/2012/814795
Hambidge, K. M., and Krebs, N. F. (2007). Zinc deficiency: a special challenge. J.
Nutr. 137, 1101–1105.
Hamre, H. (1995). [Chronic fatigue syndrome–a review of the literature]. [Article
in Norwegian]. Tidsskr Nor Laegeforen. 115, 3042–3045.
Hao, Y., Yang, X., Chen, C., Yuan-Wang., Wang, X., Li, M., et al. (2010).
STAT3 signalling pathway is involved in the activation of microglia
induced by 2.45 GHz electromagnetic fields. Int. J. Radiat. Biol. 86, 27–36.
doi: 10.3109/09553000903264507
Hardingham, G. E., Fukunaga, Y., and Bading, H. (2002). Extrasynaptic NMDARs
oppose synaptic NMDARs by triggering CREB shut-off and cell death
pathways. Nat. Neurosci. 5, 405–414. doi: 10.1038/nn835
He, J., Hollingsworth, K., Newton, J., and Blamire, A. (2013). Cerebral vascular
control is associated with skeletal muscle pH in chronic fatigue syndrome
patients both at rest and during dynamic stimulation. Neuroimage Clin. 2,
168–173. doi: 10.1016/j.nicl.2012.12.006
Heim, C., Nater, U., Maloney, E., Boneva, R., Jones, J., and Reeves,
W. (2009). Childhood trauma and risk for chronic fatigue syndrome:
association with neuroendocrine dysfunction. Arch. Gen. Psychiatry 66, 72–80.
doi: 10.1001/archgenpsychiatry.2008.508
Hickie, I., Davenport, T., Wakefield, D., Vollmer-Conna, U., Cameron, B., Vernon,
S., et al. (2006). Post-infective and chronic fatigue syndromes precipitated by
viral and non-viral pathogens: prospective cohort study. BMJ 333, 575–577.
doi: 10.1136/bmj.38933.585764.AE
Hollingsworth, K., Hodgson, T., Macgowan, G., Blamire, A., and Newton, J.
(2012). Impaired cardiac function in chronic fatigue syndrome measured
using magnetic resonance cardiac tagging. J. Intern. Med. 271, 264–270.
doi: 10.1111/j.1365-2796.2011.02429.x
Hooper, D. G., Bolton, V. E., Guilford, F., and Straus, D. (2009). Mycotoxin
detection in human samples from patients exposed to environmental molds.
Int. J. Mol. Sci. 10, 1465–1475. doi: 10.3390/ijms10041465
Hulsebosch, C. (2008). Gliopathy ensures persistent inflammation
and chronic pain after spinal cord injury. Exp. Neurol. 214, 6–9.
doi: 10.1016/j.expneurol.2008.07.016
Ickmans, K., Meeus, M., De Kooning, M., Lambrecht, L., Pattyn, N., and Nijs,
J. (2015). Associations between cognitive performance and pain in chronic
fatigue syndrome: comorbidity with Fibromyalgia does matter. Pain Phys. 18,
E841–E852. doi: 10.1016/j.physio.2015.03.3465
Ifuku, M., Hossain, S., Noda, M., and Katafuchi, T. (2014). Induction of
interleukin-1β by activated microglia is a prerequisite for immunologically
induced fatigue. Eur. J. Neurosci. 40, 3253–3263. doi: 10.1111/ejn.12668
Jason, L., Benton, M., Torres-Harding, S., and Muldowney, K. (2009).
The impact of energy modulation on physical functioning and fatigue
severity among patients with ME/CFS. Patient Educ. Couns. 77, 237–241.
doi: 10.1016/j.pec.2009.02.015
Jason, L. A., Corradi, K., Gress, S., Williams, S., and Torres-Harding, S. (2006).
Causes of death among patients with chronic fatigue syndrome. Health Care
Women Int. 27, 615–626. doi: 10.1080/07399330600803766
Jason, L., Sorenson, M., Porter, N., and Belkairous, N. (2011). An etiological model
for myalgic encephalomyelitis/chronic fatigue syndrome. Neurosci. Med. 2,
14–27. doi: 10.4236/nm.2011.21003
Ji, R. R., Berta, T., and Nedergaard, M. (2013). Glia and pain: is chronic pain a
gliopathy? Pain 154 (Suppl. 1), S10–S28. doi: 10.1016/j.pain.2013.06.022
Jones, D., Hollingsworth, K., Taylor, R., Blamire, A., and Newton, J. (2010).
Abnormalities in pH handling by peripheral muscle and potential regulation
by the autonomic nervous system in chronic fatigue syndrome. J. Intern. Med.
267, 394–401. doi: 10.1111/j.1365-2796.2009.02160.x
Frontiers in Physiology | www.frontiersin.org 7 February 2017 | Volume 8 | Article 88
Glassford The Neuroinflammatory Etiopathology of ME/CFS
Kavelaars, A., Kuis, W., Knook, L., Sinnema, G., and Heijnen, C. (2000). Disturbed
neuroendocrine-immune interactions in chronic fatigue syndrome. J. Clin.
Endocrinol. Metab. 85, 692–696. doi: 10.1210/jcem.85.2.6379
Lengert, N., and Drossel, B. (2015). In silico analysis of exercise intolerance
in myalgic encephalomyelitis/chronic fatigue syndrome. Biophys. Chem. 202,
21–31. doi: 10.1016/j.bpc.2015.03.009
Leon, R., Wu, H., Jin, Y., Wei, J., Buddhala, C., Prentice, H., et al. (2009). Protective
function of taurine in glutamate-induced apoptosis in cultured neurons. J.
Neurosci. Res. 87, 1185–1194. doi: 10.1002/jnr.21926
Liang, G., Cline, G., and Macica, C. (2007). IGF-1 stimulates de novo fatty
acid biosynthesis by Schwann cells during myelination. Glia 55, 632–641.
doi: 10.1002/glia.20496
Light, K., Agarwal, N., Iacob, E., White, A., Kinney, A., VanHaitsma, T.,
et al. (2013). Differing leukocyte gene expression profiles associated with
fatigue in patients with prostate cancer versus Chronic Fatigue Syndrome.
Psychoneuroendocrinology 38, 2983–2995. doi: 10.1016/j.psyneuen.2013.08.008
Longoni, M., and Ferrarese, C. (2006). Inflammation and excitotoxicity:
role in migraine pathogenesis. Neurol. Sci. 27(Suppl. 2), S107–S110.
doi: 10.1007/s10072-006-0582-2
Löscher, W., and Ebert, U. (1996). The role of the piriform cortex in kindling. Prog.
Neurobiol. 50, 427–481. doi: 10.1016/S0301-0082(96)00036-6
Maes, M., and Twisk, F. (2010). Chronic fatigue syndrome: Harvey and
Wessely’s (bio)psychosocial model versus a bio(psychosocial) model based on
inflammatory and oxidative and nitrosative stress pathways. BMC Med. 8:35.
doi: 10.1186/1741-7015-8-35
Mailankot, M., Kunnath, A. P., Jayalekshmi, H., Koduru, B., and Valsalan,
R. (2009). Radio frequency electromagnetic radiation (RF-EMR) from
GSM (0.9/1.8GHz) mobile phones induces oxidative stress and reduces
sperm motility in rats. Clinics 64, 561–565. doi: 10.1590/S1807-59322009000
600011
Marshall-Gradisnik, S., Smith, P., Brenu, E., Nilius, B., Ramos, S., and Staines, D.
(2015). Examination of Single Nucleotide Polymorphisms (SNPs) in Transient
Receptor Potential (TRP) ion channels in Chronic Fatigue Syndrome patients.
Immunol. Immunogenet. Insights 7, 1–6. doi: 10.4137/III.S25147
Mason, J., Ye, P., Suzuki, K., D’Ercole, A., and Matsushima, G. (2000). Insulin-
like growth factor-1 inhibits mature oligodendrocyte apoptosis during primary
demyelination. J Neurosci. 20, 5703–5708.
Meeus, M., and Nijs, J. (2007). Central sensitization: a biopsychosocial explanation
for chronic widespread pain in patients with fibromyalgia and chronic
fatigue syndrome. Clin. Rheumatol. 26, 465–473. doi: 10.1007/s10067-006-
0433-9
Milrad, S., Hall, D., Jutagir, D., Lattie, E., Ironson, G., Wohlgemuth, W.,
et al. (2017). Poor sleep quality is associated with greater circulating
pro-inflammatory cytokines and severity and frequency of chronic fatigue
syndrome/myalgic encephalomyelitis (CFS/ME) symptoms in women. J.
Neuroimmunol. 303, 43–50. doi: 10.1016/j.jneuroim.2016.12.008
Miwa, K. (2015). Cardiac dysfunction and orthostatic intolerance in patients with
myalgic encephalomyelitis and a small left ventricle.Heart Vessels 30, 484–489.
doi: 10.1007/s00380-014-0510-y
Mohebiany, A. N., and Schneider, R. (2013). Glutamate Excitotoxicity
in the cerebellum mediated by IL-1β. J. Neurosci. 33, 18353–18355.
doi: 10.1523/jneurosci.3946-13.2013
Mörl, F., and Bradl, I. (2013). Lumbar posture and muscular activity
while sitting during office work. J. Electromyogr. Kinesiol. 23, 362–368.
doi: 10.1016/j.jelekin.2012.10.002
Morris, G., and Maes, M. (2012). A neuro-immune model of Myalgic
Encephalomyelitis/Chronic fatigue syndrome. Metab. Brain Dis. 28, 523–540.
doi: 10.1007/s11011-012-9324-8
Morris, G., and Maes, M. (2013). Myalgic encephalomyelitis/chronic fatigue
syndrome and encephalomyelitis disseminata/multiple sclerosis show
remarkable levels of similarity in phenomenology and neuroimmune
characteristics. BMCMed. 11:205. doi: 10.1186/1741-7015-11-205
Myhill, S., Booth, N., and Mclaren-Howard, J. (2009). Chronic fatigue syndrome
and mitochondrial dysfunction. Int. J. Clin. Exp. Med. 2, 1–16.
Nakatomi, Y., Mizuno, K., Ishii, A., Wada, Y., Tanaka, M., Tazawa, S., et al. (2014).
Neuroinflammation in patients with Chronic Fatigue Syndrome/Myalgic
Encephalomyelitis: an 11C-(R)-PK11195 PET study. J. Nucl. Med. 55, 945–950.
doi: 10.2967/jnumed.113.131045
Narita, M., Nishigami, N., Narita, N., Yamaguti, K., Okado, N., Watanabe, Y.,
et al. (2003). Association between serotonin transporter gene polymorphism
and chronic fatigue syndrome. Biochem. Biophys. Res. Commun. 311, 264–266.
doi: 10.1016/j.bbrc.2003.09.207
Nicolson, G., Gan, R., and Haier, J. (2003). Multiple co-infections (Mycoplasma,
Chlamydia, human herpes virus-6) in blood of chronic fatigue syndrome
patients: association with signs and symptoms. APMIS 111, 557–566.
doi: 10.1034/j.1600-0463.2003.1110504.x
Nijs, J., Meeus, M., Van Oosterwijck, J., Ickmans, K., Moorkens, G., Hans,
G., et al. (2013). Fear of movement and avoidance behaviour toward
physical activity in chronic-fatigue syndrome and fibromyalgia: state of the
art and implications for clinical practice. Clin. Rheumatol. 32, 1121–1129.
doi: 10.1007/s10067-013-2277-4
Nijs, J., Roussel, N., Van Oosterwijck, J., De Kooning, M., Ickmans, K., Struyf,
F., et al. (2012). In the mind or in the brain? Scientific evidence for central
sensitisation in chronic fatigue syndrome. Eur. J. Clin Invest. 42, 203–212.
doi: 10.1111/j.1365-2362.2011.02575.x
Norden, D., and Godbout, J. (2012). Review: microglia of the aged brain: primed
to be activated and resistant to regulation. Neuropathol. Appl. Neurobiol. 39,
19–34. doi: 10.1111/j.1365-2990.2012.01306.x
Ocon, A. (2013). Caught in the thickness of brain fog: exploring the
cognitive symptoms of Chronic Fatigue Syndrome. Front. Physiol. 4:63.
doi: 10.3389/fphys.2013.00063
Oldstone, M. (1989). Viral alteration of cell function. Sci. Am. 261, 42–48.
Pall, M. (2003). Elevated nitric oxide/peroxynitrite theory of multiple chemical
sensitivity: central role of N-methyl-D-aspartate receptors in the sensitivity
mechanism. Environ. Health Perspect. 111, 1461–1464. doi: 10.1289/ehp.5935
Pall, M. (2007). Explaining Unexplained Illnesses: Disease Paradigm for Chronic
Fatigue Syndrome, Multiple Chemical Sensitivity, Fibromyalgia, Post-Traumatic
Stress Disorder, Gulf War Syndrome, and Others. New York, NY: Harrington
Park Press.
Pall, M. (2016). Microwave frequency electromagnetic fields (EMFs) produce
widespread neuropsychiatric effects including depression. J. Chem. Neuroanat.
75, 43–51. doi: 10.1016/j.jchemneu.2015.08.001
Paul, L., Wood, L., Behan,W., andMaclaren,W. (1999). Demonstration of delayed
recovery from fatiguing exercise in chronic fatigue syndrome. Eur. J. Neurol. 6,
63–69. doi: 10.1046/j.1468-1331.1999.610063.x
Perrin, R. (2007). The Perrin Technique: How to Beat Chronic Fatigue Syndrome.
London: Hammersmith.
Posnett, D. N., and Yarilin, D. (2005). Amplification of autoimmune disease by
infection. Arthritis Res. Ther. 7, 74–84. doi: 10.1186/ar1691
Prins, Y., Crous, L., and Louw, Q. (2008). A systematic review of posture
and psychosocial factors as contributors to upper quadrant musculoskeletal
pain in children and adolescents. Physiother. Theory Pract. 24, 221–242.
doi: 10.1080/09593980701704089
Puche, J. E., and Castilla-Cortázar, I. (2012). Human conditions of
insulin-like growth factor-I (IGF-I) deficiency. J. Transl. Med. 10:224.
doi: 10.1186/1479-5876-10-224
Puri, B., Jakeman, P., Agour, M., Gunatilake, K., Fernando, K., Gurusinghe, A.,
et al. (2012). Regional grey and white matter volumetric changes in myalgic
encephalomyelitis (chronic fatigue syndrome): a voxel-based morphometry 3
T MRI study. Br. J. Radiol. 85, e270–e273. doi: 10.1259/bjr/93889091
Raison, C., Lin, J., and Reeves, W. (2009). Association of peripheral inflammatory
markers with chronic fatigue in a population-based sample. Brain Behav.
Immun. 23, 327–337. doi: 10.1016/j.bbi.2008.11.005
Rayhan, R. U., Ravindran, M., and Baraniuk, J. (2013). Migraine in gulf war
illness and chronic fatigue syndrome: prevalence, potential mechanisms, and
evaluation. Front. Physiol. 4:181. doi: 10.3389/fphys.2013.00181
Ren, K., and Dubner, R. (2008). Neuron-glia crosstalk gets serious:
role in pain hypersensitivity. Curr. Opin. Anaesthesiol. 21, 570–579.
doi: 10.1097/ACO.0b013e32830edbdf
Renno, T., Krakowski, M., Piccirillo, C., Lin, J., and Owens, T. (1995). TNF-
alpha expression by resident microglia and infiltrating leukocytes in the
central nervous system of mice with experimental allergic encephalomyelitis.
Regulation by Th1 cytokines. J Immunol. 154, 944–953.
Reyes, M., Nisenbaum, R., Hoaglin, D., Unger, E., Emmons, C., Randall, B., et al.
(2003). Prevalence and incidence of chronic fatigue syndrome in Wichita,
Kansas. Arch. Intern. Med. 163, 1530–1536. doi: 10.1001/archinte.163.13.1530
Frontiers in Physiology | www.frontiersin.org 8 February 2017 | Volume 8 | Article 88
Glassford The Neuroinflammatory Etiopathology of ME/CFS
Ricci, G., Volpi, L., Pasquali, L., Petrozzi, L., and Siciliano, G. (2009). Astrocyte–
neuron interactions in neurological disorders. J. Biol. Phys. 35, 317–336.
doi: 10.1007/s10867-009-9157-9
Rowe, P., Barron, D., Calkins, H., Maumenee, I., Tong, P., and Geraghty,
M. (1999). Orthostatic intolerance and chronic fatigue syndrome
associated with Ehlers-Danlos syndrome. J. Pediatr. 135, 494–499.
doi: 10.1016/S0022-3476(99)70173-3
Rowe, P., Fontaine, K., Lauver, M., Jasion, S., Marden, C., Moni, M., et al.
(2016). Neuromuscular strain increases symptom intensity in chronic fatigue
syndrome. PLoS ONE 11:e0159386. doi: 10.1371/journal.pone.0159386
Rowe, P., Fontaine, K., and Violand, R. (2013). Neuromuscular strain as
a contributor to cognitive and other symptoms in chronic fatigue
syndrome: hypothesis and conceptual model. Front. Physiol. 4:115.
doi: 10.3389/fphys.2013.00115
Rowe, P., Marden, C., Flaherty, M., Jasion, S., Cranston, E., Johns, A., et al. (2014).
Impaired range of motion of limbs and spine in chronic fatigue syndrome. J.
Pediatr. 165, 360–366. doi: 10.1016/j.jpeds.2014.04.051
Rowland, R., Podd, J., Rapley, B., and Maisch, D. (1998). Chronic fatigue
syndrome - is prolonged exposure to environmental level powerline frequency
electromagnetic fields a co-factor to consider in treatment? ANCEM 17, 29–35.
Sankar, S., Manivasagam, T., Krishnamurti, A., and Ramanathan, M. (2007). The
neuroprotective effect of Withania somnifera root extract in MPTP-intoxicated
mice: an analysis of behavioral and biochemical variables. Cell. Mol. Biol. Lett.
12, 473–481. doi: 10.2478/s11658-007-0015-0
Schuh-Hofer, S., Wodarski, R., Pfau, D., Caspani, O., Magerl, W., Kennedy, J., et al.
(2013). One night of total sleep deprivation promotes a state of generalized
hyperalgesia: a surrogate pain model to study the relationship of insomnia and
pain. Pain 154, 1613–1621. doi: 10.1016/j.pain.2013.04.046
Schwartzman, R. (2012). Systemic complications of complex regional pain
syndrome. Neurosci. Med. 3, 225–242. doi: 10.4236/nm.2012.33027
Shanks, L., Jason, L., Evans, M., and Brown, A. (2013). Cognitive
impairments associated with CFS and POTS. Front. Physiol. 4:113.
doi: 10.3389/fphys.2013.00113
Smith, A., and Thomas, M. (2015). Chronic fatigue syndrome and increased
susceptibility to upper respiratory tract infections and illnesses. Fatigue Biomed.
Health Behav. 3, 156–163. doi: 10.1080/21641846.2015.1033271
Staud, R., Mokthech, M., Price, D., and Robinson, M. (2015). Evidence for
sensitized fatigue pathways in patients with chronic fatigue syndrome. Pain 156,
750–759. doi: 10.1097/j.pain.0000000000000110
VanElzakker, M. (2013). Chronic fatigue syndrome from vagus nerve infection:
a psychoneuroimmunological hypothesis. Med. Hypothese. 81, 414–423.
doi: 10.1016/j.mehy.2013.05.034
VanNess, J., Stevens, S., Bateman, L., Stiles, T., and Snell, C. (2010). Postexertional
malaise in women with chronic fatigue syndrome. J. Womens Health 19,
239–244. doi: 10.1089/jwh.2009.1507
Vecchiet, L., Montanari, G., Pizzigallo, E., Iezzi, S., de Bigontina, P., Dragani,
L., et al. (1996). Sensory characterization of somatic parietal tissues in
humans with chronic fatigue syndrome. Neurosci. Lett. 208, 117–120.
doi: 10.1016/0304-3940(96)12559-3
Velizarov, S., Raskmark, P., and Kwee, S. (1999). The effects of radiofrequency
fields on cell proliferation are non-thermal. Bioelectrochem. Bioenerg. 48,
177–180. doi: 10.1016/S0302-4598(98)00238-4
Visser, J., Lentjes, E., Haspels, I., Graffelman, W., Blauw, B., de Kloet, R.,
et al. (2001). Increased sensitivity to glucocorticoids in peripheral blood
mononuclear cells of chronic fatigue syndrome patients, without evidence
for altered density or affinity of glucocorticoid receptors. J. Investig. Med. 49,
195–204. doi: 10.2310/6650.2001.34047
Vollmer-Conna, U., Piraino, B., Cameron, B., Davenport, T., Hickie, I., Wakefield,
D., et al. (2008). Cytokine polymorphisms have a synergistic effect on severity
of the acute sickness response to infection. Clin. Infect. Dis. 47, 1418–1425.
doi: 10.1086/592967
Winger, A., Kvarstein, G., Wyller, V., Ekstedt, M., Sulheim, D., Fagermoen,
E., et al. (2015). Health related quality of life in adolescents with chronic
fatigue syndrome: a cross-sectional study. Health Qual. Life Outcomes 13:96.
doi: 10.1186/s12955-015-0288-3
Woolf, C. (1991). Generation of acute pain: central mechanisms. Br. Med. Bull. 47,
523–533.
Woolf, C. (2011). Central sensitization: implications for the diagnosis and
treatment of pain. Pain 152(Suppl.), S2–S15. doi: 10.1016/j.pain.2010.09.030
Xie, L., Kang, H., Xu, Q., Chen, M., Liao, Y., Thiyagarajan, M., et al. (2013).
Sleep drives metabolite clearance from the adult brain. Science 342, 373–377.
doi: 10.1126/science.1241224
Yasui, M., Yoshimura, T., Takeuchi, S., Tokizane, K., Tsuda, M., Inoue, K., et al.
(2014). A Chronic fatigue syndrome model demonstrates mechanical allodynia
and muscular hyperalgesia via spinal microglial activation. Glia 62, 1407–1417.
doi: 10.1002/glia.22687
Younger, J., Noor, N., Mccue, R., and Mackey, S. (2013). Low-dose naltrexone for
the treatment of fibromyalgia: findings of a small, randomized, double-blind,
placebo-controlled, counterbalanced, crossover trial assessing daily pain levels.
Arthritis Rheum. 65, 529–538. doi: 10.1002/art.37734
Zoccolella, S., Santamato, A., and Lamberti, P. (2009). Current and emerging
treatments for amyotrophic lateral sclerosis. Neuropsychiatr. Dis. Treat. 5,
577–595. doi: 10.2147/NDT.S7788
Conflict of Interest Statement: The author declares that the research was
conducted in the absence of any commercial or financial relationships that could
be construed as a potential conflict of interest.
Copyright © 2017 Glassford. This is an open-access article distributed under the
terms of the Creative Commons Attribution License (CC BY). The use, distribution or
reproduction in other forums is permitted, provided the original author(s) or licensor
are credited and that the original publication in this journal is cited, in accordance
with accepted academic practice. No use, distribution or reproduction is permitted
which does not comply with these terms.
Frontiers in Physiology | www.frontiersin.org 9 February 2017 | Volume 8 | Article 88
